
Ivantis was a medical device company developing the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure in patients with primary open-angle glaucoma. The company's device received FDA clearance and was subsequently acquired by Alcon in January 2022 for $475 million.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account